$XBIO SEC Filings

Filed On	Filing
23 Sep 2026	8-K: Regulation FD Disclosure Advancing NET - Targeted Therapies for Immune - Driven Diseases and Cancer INVESTOR PRESENTATION SEPTEMBER 2026
18 Sep 2026	SCHEDULE 13G
16 Sep 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more ______________________________________________________________________________
07 Aug 2026	8-K: Results of Operations and Financial Condition
06 Aug 2026	FORM 10-Q FOR JUN 2026
29 May 2026	SCHEDULE 13G
14 May 2026	SCHEDULE 13G/A
13 May 2026	8-K: Results of Operations and Financial Condition
12 May 2026	QUARTERLY REPORT FOR MARCH 2026
24 Apr 2026	FORM 10-K FOR DEC 2025 AMENDMENT 1
24 Apr 2026	8-K: Departure/Election of Directors or Officers; Compensation
23 Apr 2026	Form 4: Parslow James F, Interim CEO and CFO Received 100,000 shares as a grant or award
13 Mar 2026	8-K: Results of Operations and Financial Condition
12 Mar 2026	FORM 10-K FOR DEC 2025
12 Feb 2026	SCHEDULE 13G
09 Jan 2026	8-K: Other Events
05 Jan 2026	Form 4: Vinogradov Alexey Andreevich, Director Granted 2,500 Stock Options
05 Jan 2026	Form 4: Dastoor Firdaus J., Director Granted 2,500 Stock Options
05 Jan 2026	Form 4: Kornberg Roger D., Director Granted 2,500 Stock Options
05 Jan 2026	Form 4: Borisenko Grigory G., Director Granted 2,500 Stock Options

Comments